References
- Alidoost F, Gharagozloo M, Bagherpour B, et al. Effects of silymarin on the proliferation and glutathione levels of peripheral blood mononuclear cells from beta-thalassemia major patients. Int Immunopharmacol. 2006;6:1305–1310.
- Chao T, Wang H, Ho PC. Mitochondrial control and guidance of cellular activities of T cells. Front Immunol. 2017;8:473.
- Darzynkiewicz Z, Traganos F, Staiano-Coico L, Kapuscinski J, Melamed MR. Interaction of rhodamine 123 with living cells studied by flow cytometry. Cancer Res. 1982;42:799–806.
- Dwyer JM, Johnson C. The use of concanavalin A to study the immunoregulation of human T cells. Clin Exp Immunol. 1981;46:237–249.
- Esmaeil N, Anaraki SB, Gharagozloo M, Moayedi B. Silymarin impacts on immune system as an immunomodulator: One key for many locks. Int Immunopharmacol. 2017;50:194–201.
- Feuerer M, Hill JA, Mathis D, Benoist C. Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol. 2009;10:689–695.
- Fraschini F, Demartini G, Esposti D. Pharmacology of Silymarin. Clin Drug Invest. 2002;22:51–65.
- Gažák R, Walterova D, Kren V. Silybin and silymarin--new and emerging applications in medicine. Curr Med Chem. 2007;14:315–338.
- Gharagozloo M, Javid EN, Rezaei A, Mousavizadeh K. Silymarin inhibits cell cycle progression and mTOR activity in activated human T cells: therapeutic implications for autoimmune diseases. Basic Clin Pharmacol Toxicol. 2013;112:251–256.
- Gharagozloo M, Velardi E, Bruscoli S, et al. Silymarin suppress CD4+ T cell activation and proliferation: effects on NF-kappaB activity and IL-2 production. Pharmacol Res. 2010;61:405–409.
- Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057–1061.
- Johnson VJ, He Q, Osuchowski MF, Sharma RP. Physiological responses of a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: III. Silymarin inhibits T-lymphocyte function at low doses but stimulates inflammatory processes at high doses. Planta Med. 2003;69:44–49.
- Karimi G, Hassanzadeh-Josan S, Memar B, Esmaeili SA, Riahi-Zanjani B. Immunomodulatory effects of silymarin after subacute exposure to mice: A tiered approach immunotoxicity screening. J Pharmacopuncture. 2018;21:90–97.
- Krauss S, Buttgereit F, Brand MD. Effects of the mitogen concanavalin A on pathways of thymocyte energy metabolism. Biochim Biophys Acta. 1999;1412:129–138.
- Kulkarni GV, Lee W, Seth A, McCulloch CA. Role of mitochondrial membrane potential in concanavalin A-induced apoptosis in human fibroblasts. Exp Cell Res. 1998;245:170–178.
- Kwon DY, Jung YS, Kim SJ, Kim YS, Choi DW, Kim YC. Alterations in sulfur amino acid metabolism in mice treated with silymarin: a novel mechanism of its action involved in enhancement of the antioxidant defense in liver. Planta Med. 2013;79:997–1002.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408.
- Lovelace ES, Maurice NJ, Miller HW, et al. Silymarin suppresses basal and stimulus-induced activation, exhaustion, differentiation, and inflammatory markers in primary human immune cells. PloS one. 2017;12:e0171139–e0171139.
- Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol. 1999;163:6800–6809.
- Namdari H, Izad M, Rezaei F, Amirghofran Z. Differential regulation of CD4(+) T cell subsets by Silymarin in vitro and in ovalbumin immunized mice. Daru. 2018;26:215–227.
- O’Neill LA, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. 2016;16:553–565.
- O’Sullivan D, Pearce EL. Targeting T cell metabolism for therapy. Trends Immunol. 2015;36:71–80.
- Ozay EI, Sherman HL, Mello V, et al. Rotenone treatment reveals a role for electron transport complex i in the subcellular localization of key transcriptional regulators during T helper cell differentiation. Front Immunol. 2018;9:1284.
- Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett. 2008;269:352–362.
- Robertson JD, Orrenius S. Molecular mechanisms of apoptosis induced by cytotoxic chemicals. Crit Rev Toxicol. 2000;30:609–627.
- Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61:2035–2063.
- Shinohara Y, Tsukimoto M. Adenine nucleotides attenuate murine T cell activation induced by Concanavalin A or T cell receptor stimulation. Front Pharmacol. 2018;8:986.
- Surai PF. Silymarin as a Natural Antioxidant: An overview of the current evidence and perspectives. Antioxidants (Basel). 2015;4:204–247.
- Wang JL, Cunningham BA, Edelman GM. Unusual fragments in the subunit structure of concanavalin A. Proc Natl Acad Sci U S A. 1971;68:1130–1134.
- Wilasrusmee C, Kittur S, Shah G, et al. Immunostimulatory effect of Silybum Marianum (milk thistle) extract. Med Sci Monit. 2002;8:Br439–443.
- Yuan J. Divergence from a dedicated cellular suicide mechanism: exploring the evolution of cell death. Mol Cell. 2006;2:1–12.
- Zhao J, Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis. 1999;20:2101–2108.